TickerHumSide-by-side comparison
Bristol-Myers Squibb vs Merck & Co.
As of Nov 11, 2026, P/E is 13.8x for Bristol-Myers Squibb vs 147.9x for Merck & Co.; P/S is 2.5x for Bristol-Myers Squibb vs 5.4x for Merck & Co.; revenue growth is 4.2% for Bristol-Myers Squibb vs 4.9% for Merck & Co.; net margin is 18.5% for Bristol-Myers Squibb vs 3.6% for Merck & Co..
What stands out
- Bristol-Myers Squibb is cheaper on earnings: 13.8x P/E vs 147.9x for Merck & Co..
- Merck & Co. carries less debt relative to equity: 1.11 vs 1.79 for Bristol-Myers Squibb.
- Merck & Co.'s shares did better over the past year: +60.1% vs +27.0% for Bristol-Myers Squibb.
- Bristol-Myers Squibb scores higher on TickerHum's ratings: 69/100 vs 50/100 for Merck & Co..
Key metrics
| Metric | BMY | MRK |
|---|---|---|
| Price | $62.32 | $146.45 |
| Market cap | $127.39B | $361.04B |
| P/E | 13.8x (#1) | 147.9x (#2) |
| P/S | 2.5x (#1) | 5.4x (#2) |
| Revenue growth | 4.2% (#2) | 4.9% (#1) |
| Operating margin | — | — |
| Net margin | 18.5% (#1) | 3.6% (#2) |
| Debt / equity | 1.79 (#2) | 1.11 (#1) |
| 1-year return | +27.0% (#2) | +60.1% (#1) |
| Research score | 69/100 (#1) | 50/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General